e 4031 has been researched along with Cancer of Liver in 2 studies
E 4031: class III anti-arrhythmia agent; structure given in UD
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, D | 1 |
| Kang, JA | 1 |
| Lim, C | 1 |
| Bae, S | 1 |
| Choi, J | 1 |
| Park, M | 1 |
| Kim, YC | 1 |
| Cho, Y | 1 |
| Park, SG | 1 |
| Seo, J | 1 |
| Abu Rabah, RR | 1 |
| Sebastian, A | 1 |
| Vunnam, S | 1 |
| Sultan, S | 1 |
| Tarazi, H | 1 |
| Anbar, HS | 1 |
| Shehata, MK | 1 |
| Zaraei, SO | 1 |
| Elgendy, SM | 1 |
| Al Shamma, SA | 1 |
| Omar, HA | 1 |
| Al-Tel, TH | 1 |
| El-Gamal, MI | 1 |
2 other studies available for e 4031 and Cancer of Liver
| Article | Year |
|---|---|
Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
Topics: Antiviral Agents; Cyclosporins; Hepatitis B; Hepatitis B virus; Humans; Imidazoles; Liver Neoplasms; | 2022 |
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant | 2022 |